#HAE #HereditaryAngioedema #HaeWarrior #HAEKids #PediatricHAE #RareDisease #RareDiseaseCommunity #ChronicIllness #OnDemandTreatment #Ekterly #Sebetralstat ##RareButNotAlone #CaregiverLife #ClinicalTrials #BioNews #AngioedemaNews

Read how oral treatments are making a difference where it counts.

#Angioedema #HAE #ChildhoodChronicIllness #Ekterly #RareDisease #AngioedemaNews #Bionews

#HAE #HereditaryAngioedema #Ekterly #Sebetralstat #OralHAETreatment #OnDemandTherapy #ChronicIllness #RareDisease #Angioedema #PatientEmpowerment #SwellingRelief #SpoonieLife #HAECommunity #KalVista #BioNews #AngioedemaNews

If approved this October, patients may soon have a new needle‑free option to manage swelling
episodes quickly and confidently.

#HereditaryAngioedema #HAE #RareDisease #Sebetralstat #Ekterly #OrphanDrug #KalVista #OnDemandTherapy #BioNews #AngioedemaNews

Orsini Chosen as Specialty Pharmacy Partner for KalVista's EKTERLY® Treatment Orsini has been selected by KalVista Pharmaceuticals as a specialty pharmacy partner for EKTERLY®, a new oral therapy for hereditary angioedema.

Orsini Chosen as Specialty Pharmacy Partner for KalVista's EKTERLY® Treatment #United_States #Elk_Grove_Village #Orsini #KalVista #EKTERLY